Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.
2.

A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.

Johnson DW, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM; HERO Study Collaborative Group..

Am J Kidney Dis. 2015 Jan;65(1):49-57. doi: 10.1053/j.ajkd.2014.06.020.

PMID:
25115616
3.

Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.

Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF.

Cochrane Database Syst Rev. 2014 Dec 8;(12):CD010590. doi: 10.1002/14651858.CD010590.pub2. Review.

PMID:
25486075
4.

Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.

Winkelmayer WC, Chang TI, Mitani AA, Wilhelm-Leen ER, Ding V, Chertow GM, Brookhart MA, Goldstein BA.

Am J Kidney Dis. 2015 Jul;66(1):106-13. doi: 10.1053/j.ajkd.2015.02.339.

5.

Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.

Skali H, Lin J, Pfeffer MA, Chen CY, Cooper ME, McMurray JJ, Nissenson AR, Remuzzi G, Rossert J, Parfrey PS, Scott-Douglas NW, Singh AK, Toto R, Uno H, Ivanovich P.

Am J Kidney Dis. 2013 Feb;61(2):238-46. doi: 10.1053/j.ajkd.2012.08.043.

PMID:
23159232
6.

Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.

Nordstrom BL, Luo W, Fraeman K, Whyte JL, Nordyke RJ.

J Manag Care Pharm. 2008 Nov-Dec;14(9):858-69.

7.

Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.

Alsalimy N, Awaisu A.

Int J Clin Pharm. 2014 Dec;36(6):1115-25. doi: 10.1007/s11096-014-0023-x. Review.

PMID:
25288147
8.

Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.

Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL.

Am J Kidney Dis. 2013 Jan;61(1):44-56. doi: 10.1053/j.ajkd.2012.07.014.

9.

Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.

Aspinall SL, Cunningham FE, Zhao X, Boresi JS, Tonnu-Mihara IQ, Smith KJ, Stone RA, Good CB; ESA Clinic Study Group..

Am J Kidney Dis. 2012 Sep;60(3):371-9. doi: 10.1053/j.ajkd.2012.04.013.

PMID:
22633556
10.

Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?

Berns JS.

Curr Opin Nephrol Hypertens. 2010 Nov;19(6):567-72. doi: 10.1097/MNH.0b013e32833c3cc7. Review.

PMID:
20601876
11.

Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.

Maddux FW, Shetty S, del Aguila MA, Nelson MA, Murray BM.

Ann Pharmacother. 2007 Nov;41(11):1761-9.

PMID:
17895328
12.

A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia.

Hörbrand F, Bramlage P, Fischaleck J, Hasford J, Brunkhorst R.

Eur J Clin Pharmacol. 2013 Apr;69(4):929-36. doi: 10.1007/s00228-012-1412-5.

PMID:
23052412
13.

Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.

Freburger JK, Ellis AR, Wang L, Butler AM, Kshirsagar AV, Winkelmayer WC, Brookhart MA.

Am J Kidney Dis. 2016 Feb;67(2):271-82. doi: 10.1053/j.ajkd.2015.09.011.

PMID:
26508682
14.

Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin.

Tsuruya K, Yoshida H, Suehiro T, Fujisaki K, Masutani K, Kitazono T.

Ren Fail. 2016;38(3):390-6. doi: 10.3109/0886022X.2015.1136874.

PMID:
26822074
15.

2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.

Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.

PMID:
20609178
16.

Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients.

Kuwahara M, Hasumi S, Mandai S, Tanaka T, Shikuma S, Akita W, Mori Y, Sasaki S.

Clin Exp Nephrol. 2014 Oct;18(5):755-62. doi: 10.1007/s10157-013-0919-0.

PMID:
24317507
17.

Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.

Horowitz J, Agarwal A, Huang F, Gitlin M, Gandra SR, Cangialose CB.

J Manag Care Pharm. 2009 Nov-Dec;15(9):741-50.

18.

Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill J, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, Uno H; TREAT Investigators..

Am J Kidney Dis. 2009 Jul;54(1):59-69. doi: 10.1053/j.ajkd.2009.04.008.

PMID:
19501439
19.
20.

Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials.

Krause MW, Raja R, Agarwal A, Silver MR, Scarlata D, Sciarra A, Kewalramani R.

Drugs Aging. 2009;26(8):665-75. doi: 10.2165/11316450-000000000-00000.

Items per page

Supplemental Content

Support Center